Dr. Lamanna Discusses the MURANO Trial in CLL

Video

In Partnership With:

Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.

Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial, which evaluated the use of venetoclax and rituximab (Rituxan) combination therapy versus bendamustine and rituximab in patients with chronic lymphocytic leukemia (CLL).

This was the follow-up trial to initial phase I data that supported the tolerability and efficacy of the combination. The next step, according to Lamanna, was to compare the venetoclax combination regimen with the standard of care, a chemoimmunotherapy combination comprised of bendamustine and rituximab.

Three-year follow-up data on the feasibility of fixed-duration venetoclax were presented at the 2018 ASH Annual Meeting. Emerging novel agents such as BTK inhibitors are currently being used indefinitely in patients with CLL, and so the rationale for the follow-up analysis was to determine if therapy could be limited without hindering effectiveness of the treatment.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD